)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Vir Biotechnology (VIR) investor relations material
Vir Biotechnology Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Advanced hepatitis delta and oncology pipelines, with all ECLIPSE registrational studies enrolling and first patient dosed in Phase 1 study of VIR-5525 in July 2025, expanding the oncology pipeline to three ongoing Phase 1 studies.
Strategic realignment and restructuring led to cost savings, including phasing out certain research programs and site closures.
Diversified pipeline includes siRNA, antibody, and masked T-cell engager platforms, with multiple assets in Phase 1–3 trials.
No material legal proceedings or off-balance sheet arrangements reported.
Focus on immune system-based therapies for cancer and infectious diseases, with lead programs in oncology and hepatitis delta.
Financial highlights
Q2 2025 total revenues were $1.2M, down from $3.1M in Q2 2024; net loss for Q2 2025 was $111.0M, compared to $138.4M in Q2 2024.
R&D expenses for Q2 2025 were $97.5M, down from $105.1M in Q2 2024, reflecting restructuring savings.
SG&A expenses for Q2 2025 were $22.3M, down from $30.3M in Q2 2024, due to headcount reductions and restructuring.
Cash, cash equivalents, and investments totaled $892.1M as of June 30, 2025, with restricted cash of $95.2M.
Net cash consumed in Q2 2025 was $127.7M, including $50.5M in milestone payments; excluding these, net cash consumed was $77.2M.
Outlook and guidance
Cash runway projected into mid-2027, supporting advancement of key programs through value inflection points.
Focused on driving ECLIPSE study enrollment, advancing T cell engager programs, and executing business development strategies.
Anticipates providing 48-week Solstice study data by year-end and meaningful updates on T cell engager programs as data mature.
No significant revenue expected from sotrovimab or other product sales until regulatory approvals are obtained.
Multiple clinical catalysts anticipated, including pivotal HDV studies and Phase 1 oncology data.
Impact of Gilead's bulevirtide approval on HDV?
PRO-XTEN platform's dosing flexibility benefits?
Drivers of R&D spend changes?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Vir Biotechnology earnings date
Q3 202530 Oct, 2025
Next Vir Biotechnology earnings date
Q3 202530 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Vir Biotechnology Inc., a commercial-stage immunology company, specializes in developing therapeutic products aimed at treating and preventing serious infectious diseases. Leveraging its expertise in immunology, Vir Biotechnology focuses on a wide range of diseases, including viral and bacterial infections, with a particular emphasis on chronic infectious diseases like hepatitis B, tuberculosis, and HIV, as well as respiratory diseases such as influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV). The company's approach involves a multi-program, multi-platform strategy to induce protective and therapeutic immune responses. Vir Biotechnology is headquartered in San Francisco, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage